$2.33▴ 1.30%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.68MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-32.7%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 37% below our fair-value range
Balance-sheet caution
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Aytu BioPharma, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue is contracting year over year.
Key numbers
Profitability
Net margin-60.2%
TTM (trailing 12 months, through fiscal Q3 FY2026)
Size
Revenue (TTM)$56.60M
TTM (trailing 12 months, through fiscal Q3 FY2026)
Signals and key numbers are from the fiscal Q3 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.